开云app官网登录入口网页版-官方正版

#联合化疗#

120篇内容 | 2250人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1411815, encodeId=66a51411815c7, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, objectTitle=晚期NSCLC免疫疗法联合化疗 (IO-CT) 耐药的二线治疗怎么选？生存数据比较来了！丨WCLC 2022速递, objectType=article, longId=735771, objectId=6107e357712b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6107e357712b, replyNumber=0, likeNumber=79, createdTime=2022-08-14, rootId=0, userName=oliver170, userId=ebf32807001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6107e357712b, moduleTitle=晚期NSCLC免疫疗法联合化疗 (IO-CT) 耐药的二线治疗怎么选？生存数据比较来了！丨WCLC 2022速递, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6107e357712b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1411813, encodeId=a355141181373, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, objectTitle=Nat Commun：复旦大学王碧芸/胡夕春团队发现转移性三阴性乳腺癌的高效联合化疗方案, objectType=article, longId=733030, objectId=73fbe3303097, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73fbe3303097, replyNumber=0, likeNumber=76, createdTime=2022-07-24, rootId=0, userName=oliver170, userId=ebf32807001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73fbe3303097, moduleTitle=Nat Commun：复旦大学王碧芸/胡夕春团队发现转移性三阴性乳腺癌的高效联合化疗方案, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=73fbe3303097)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1411814, encodeId=1d0a141181434, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, objectTitle=2022 ASCO：派姆单抗联合化疗可显著提高早期三阴性乳腺癌的生存预后, objectType=article, longId=728384, objectId=e24ae28384d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e24ae28384d8, replyNumber=0, likeNumber=82, createdTime=2022-06-02, rootId=0, userName=oliver170, userId=ebf32807001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e24ae28384d8, moduleTitle=2022 ASCO：派姆单抗联合化疗可显著提高早期三阴性乳腺癌的生存预后, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e24ae28384d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1411812, encodeId=337d14118122d, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, objectTitle=Lancet Oncol：Adebrelimab联合化疗一线治疗广泛期小细胞肺癌, objectType=article, longId=727377, objectId=ce1ee2737728, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce1ee2737728, replyNumber=0, likeNumber=83, createdTime=2022-05-21, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce1ee2737728, moduleTitle=Lancet Oncol：Adebrelimab联合化疗一线治疗广泛期小细胞肺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ce1ee2737728)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1411811, encodeId=dead141181116, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, objectTitle=君实生物特瑞普利单抗联合化疗一线治疗食管鳞癌获得国家药品监督管理局批准, objectType=article, longId=727117, objectId=8db3e271176b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8db3e271176b, replyNumber=0, likeNumber=86, createdTime=2022-05-18, rootId=0, userName=oliver170, userId=ebf32807001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8db3e271176b, moduleTitle=君实生物特瑞普利单抗联合化疗一线治疗食管鳞癌获得国家药品监督管理局批准, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8db3e271176b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1411810, encodeId=021214118104c, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, objectTitle=BMJ：信迪利单抗联合化疗一线治疗可显著延长晚期/转移性食管鳞癌患者的生存期, objectType=article, longId=725552, objectId=9947e255526a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9947e255526a, replyNumber=0, likeNumber=97, createdTime=2022-04-28, rootId=0, userName=oliver170, userId=ebf32807001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9947e255526a, moduleTitle=BMJ：信迪利单抗联合化疗一线治疗可显著延长晚期/转移性食管鳞癌患者的生存期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9947e255526a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1411808, encodeId=201d14118085b, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, objectTitle=BMC Cancer：不可切除III期非小细胞肺癌（NSCLC）铂类放化疗进展后再给予铂类联合化疗可延长生存, objectType=article, longId=723595, objectId=19f4e2359542, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19f4e2359542, replyNumber=0, likeNumber=85, createdTime=2022-04-07, rootId=0, userName=oliver170, userId=ebf32807001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19f4e2359542, moduleTitle=BMC Cancer：不可切除III期非小细胞肺癌（NSCLC）铂类放化疗进展后再给予铂类联合化疗可延长生存, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=19f4e2359542)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1411807, encodeId=bfbb141180e30, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, objectTitle=ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）, objectType=article, longId=301717, objectId=e006301e1776, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e006301e1776, replyNumber=0, likeNumber=91, createdTime=2022-03-28, rootId=0, userName=oliver170, userId=ebf32807001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e006301e1776, moduleTitle=ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e006301e1776)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1411809, encodeId=05bb1411809c3, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, objectTitle=III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期, objectType=article, longId=301595, objectId=0e1630159509, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e1630159509, replyNumber=0, likeNumber=98, createdTime=2022-03-26, rootId=0, userName=oliver170, userId=ebf32807001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e1630159509, moduleTitle=III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0e1630159509)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1411806, encodeId=f339141180649, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, objectTitle=Transl Lung Cancer Res: 基线肿瘤大小(BTS)与NSCLC接受免疫单药或联合化疗患者预后的关系, objectType=article, longId=300887, objectId=4e8330088eb0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e8330088eb0, replyNumber=0, likeNumber=96, createdTime=2022-03-17, rootId=0, userName=oliver170, userId=ebf32807001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e8330088eb0, moduleTitle=Transl Lung Cancer Res: 基线肿瘤大小(BTS)与NSCLC接受免疫单药或联合化疗患者预后的关系, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4e8330088eb0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1411805, encodeId=436c1411805cf, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, objectTitle= 美国食品药品监督管理局（FDA）批准欧狄沃®（纳武利尤单抗）联合化疗用于特定可切除非小细胞肺癌成人患者新辅助治疗, objectType=article, longId=299862, objectId=d8d4299862bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8d4299862bd, replyNumber=0, likeNumber=70, createdTime=2022-03-03, rootId=0, userName=oliver170, userId=ebf32807001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8d4299862bd, moduleTitle= 美国食品药品监督管理局（FDA）批准欧狄沃®（纳武利尤单抗）联合化疗用于特定可切除非小细胞肺癌成人患者新辅助治疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d8d4299862bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1411804, encodeId=f782141180495, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, objectTitle=J Immunother Cancer：基线体重指数(BMI)与晚期非小细胞肺癌（NSCLC）一线免疫联合化疗治疗预后的关系, objectType=article, longId=299739, objectId=e4b0299e3991, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4b0299e3991, replyNumber=0, likeNumber=91, createdTime=2022-03-01, rootId=0, userName=oliver170, userId=ebf32807001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4b0299e3991, moduleTitle=J Immunother Cancer：基线体重指数(BMI)与晚期非小细胞肺癌（NSCLC）一线免疫联合化疗治疗预后的关系, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e4b0299e3991)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1411803, encodeId=50ce1411803d9, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, objectTitle=君实生物特瑞普利单抗联合化疗作为术后辅助治疗胃癌III期临床研究完成首例患者给药, objectType=article, longId=295432, objectId=53a8295432d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53a8295432d2, replyNumber=0, likeNumber=83, createdTime=2022-02-12, rootId=0, userName=oliver170, userId=ebf32807001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53a8295432d2, moduleTitle=君实生物特瑞普利单抗联合化疗作为术后辅助治疗胃癌III期临床研究完成首例患者给药, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=53a8295432d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1411802, encodeId=4737141180272, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, objectTitle=系统评价和荟萃分析：中医药联合化疗治疗乳腺癌, objectType=article, longId=295318, objectId=de0229531841, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de0229531841, replyNumber=0, likeNumber=0, createdTime=2022-02-10, rootId=0, userName=oliver170, userId=ebf32807001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de0229531841, moduleTitle=系统评价和荟萃分析：中医药联合化疗治疗乳腺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=de0229531841)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1411801, encodeId=42b414118013a, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, objectTitle=非鳞非小细胞肺癌EGFR阴性脑转移的治疗策略如何？CSCO二线治疗推荐没有免疫联合化疗的推荐, objectType=article, longId=294781, objectId=1a2d294e81fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a2d294e81fd, replyNumber=0, likeNumber=63, createdTime=2022-01-28, rootId=0, userName=oliver170, userId=ebf32807001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a2d294e81fd, moduleTitle=非鳞非小细胞肺癌EGFR阴性脑转移的治疗策略如何？CSCO二线治疗推荐没有免疫联合化疗的推荐, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1a2d294e81fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1411800, encodeId=3ebc14118009e, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, objectTitle=J Immunother Cancer：PD-1抑制剂联合化疗新辅助治疗可切除食管鳞状细胞癌患者的疗效, objectType=article, longId=293994, objectId=aefe293994fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aefe293994fa, replyNumber=0, likeNumber=86, createdTime=2022-01-16, rootId=0, userName=oliver170, userId=ebf32807001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aefe293994fa, moduleTitle=J Immunother Cancer：PD-1抑制剂联合化疗新辅助治疗可切除食管鳞状细胞癌患者的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aefe293994fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1411799, encodeId=fb8c1411e9947, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, objectTitle=Signal Transduct Target Ther：PD-1抑制剂Toripalimab（特瑞普利单抗）联合化疗二线治疗晚期EGFR突变NSCLC一线TKI进展后显示良好抗肿瘤疗效和可控安全性, objectType=article, longId=293109, objectId=d234293109ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d234293109ad, replyNumber=0, likeNumber=46, createdTime=2021-12-31, rootId=0, userName=oliver170, userId=ebf32807001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d234293109ad, moduleTitle=Signal Transduct Target Ther：PD-1抑制剂Toripalimab（特瑞普利单抗）联合化疗二线治疗晚期EGFR突变NSCLC一线TKI进展后显示良好抗肿瘤疗效和可控安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d234293109ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1411798, encodeId=e2381411e988b, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, objectTitle=免费回看：免疫联合化疗带来哪些突破, objectType=article, longId=292728, objectId=4404292e28ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4404292e28ff, replyNumber=0, likeNumber=84, createdTime=2021-12-26, rootId=0, userName=oliver170, userId=ebf32807001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4404292e28ff, moduleTitle=免费回看：免疫联合化疗带来哪些突破, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4404292e28ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1411797, encodeId=19a51411e974c, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, objectTitle=今日直播：免疫联合化疗带来哪些突破, objectType=article, longId=292469, objectId=f96329246966, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f96329246966, replyNumber=0, likeNumber=50, createdTime=2021-12-23, rootId=0, userName=oliver170, userId=ebf32807001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f96329246966, moduleTitle=今日直播：免疫联合化疗带来哪些突破, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f96329246966)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1411796, encodeId=3cdb1411e9649, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, objectTitle=君实生物特瑞普利单抗联合化疗一线治疗非小细胞肺癌的新适应症上市申请获受理, objectType=article, longId=259943, objectId=cceb25994367, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cceb25994367, replyNumber=0, likeNumber=83, createdTime=2021-12-12, rootId=0, userName=oliver170, userId=ebf32807001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cceb25994367, moduleTitle=君实生物特瑞普利单抗联合化疗一线治疗非小细胞肺癌的新适应症上市申请获受理, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=cceb25994367)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

联合化疗

2020-05-29

oliver170 (审核中...)

前往app查看评论内容

#联合化疗#

晚期NSCLC免疫疗法联合化疗 (IO-CT) 耐药的二线治疗怎么选？生存数据比较来了！丨WCLC 2022速递

2022-08-14

oliver170 (审核中...)

前往app查看评论内容

#联合化疗#

Nat Commun：复旦大学王碧芸/胡夕春团队发现转移性三阴性乳腺癌的高效联合化疗方案

2022-07-24

oliver170 (审核中...)

前往app查看评论内容

#联合化疗#

2022 ASCO：派姆单抗联合化疗可显著提高早期三阴性乳腺癌的生存预后

2022-06-02

仁心济世 (审核中...)

前往app查看评论内容

#联合化疗#

Lancet Oncol：Adebrelimab联合化疗一线治疗广泛期小细胞肺癌

2022-05-21

oliver170 (审核中...)

前往app查看评论内容

#联合化疗#

君实生物特瑞普利单抗联合化疗一线治疗食管鳞癌获得国家药品监督管理局批准

2022-05-18

oliver170 (审核中...)

前往app查看评论内容

#联合化疗#

BMJ：信迪利单抗联合化疗一线治疗可显著延长晚期/转移性食管鳞癌患者的生存期

2022-04-28

oliver170 (审核中...)

前往app查看评论内容

#联合化疗#

BMC Cancer：不可切除III期非小细胞肺癌（NSCLC）铂类放化疗进展后再给予铂类联合化疗可延长生存

2022-04-07

oliver170 (审核中...)

前往app查看评论内容

#联合化疗#

ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）

2022-03-28

oliver170 (审核中...)

前往app查看评论内容

#联合化疗#

III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期

2022-03-26

oliver170 (审核中...)

前往app查看评论内容

#联合化疗#

Transl Lung Cancer Res: 基线肿瘤大小(BTS)与NSCLC接受免疫单药或联合化疗患者预后的关系

2022-03-17

oliver170 (审核中...)

前往app查看评论内容

#联合化疗#

美国食品药品监督管理局（FDA）批准欧狄沃®（纳武利尤单抗）联合化疗用于特定可切除非小细胞肺癌成人患者新辅助治疗

2022-03-03

oliver170 (审核中...)

前往app查看评论内容

#联合化疗#

J Immunother Cancer：基线体重指数(BMI)与晚期非小细胞肺癌（NSCLC）一线免疫联合化疗治疗预后的关系

2022-03-01

oliver170 (审核中...)

前往app查看评论内容

#联合化疗#

君实生物特瑞普利单抗联合化疗作为术后辅助治疗胃癌III期临床研究完成首例患者给药

2022-02-12

oliver170 (审核中...)

前往app查看评论内容

#联合化疗#

系统评价和荟萃分析：中医药联合化疗治疗乳腺癌

2022-02-10

oliver170 (审核中...)

前往app查看评论内容

#联合化疗#

非鳞非小细胞肺癌EGFR阴性脑转移的治疗策略如何？CSCO二线治疗推荐没有免疫联合化疗的推荐

2022-01-28

oliver170 (审核中...)

前往app查看评论内容

#联合化疗#

J Immunother Cancer：PD-1抑制剂联合化疗新辅助治疗可切除食管鳞状细胞癌患者的疗效

2022-01-16

oliver170 (审核中...)

前往app查看评论内容

#联合化疗#

Signal Transduct Target Ther：PD-1抑制剂Toripalimab（特瑞普利单抗）联合化疗二线治疗晚期EGFR突变NSCLC一线TKI进展后显示良好抗肿瘤疗效和可控安全性

2021-12-31

oliver170 (审核中...)

前往app查看评论内容

#联合化疗#

免费回看：免疫联合化疗带来哪些突破

2021-12-26

oliver170 (审核中...)

前往app查看评论内容

#联合化疗#

今日直播：免疫联合化疗带来哪些突破

2021-12-23

oliver170 (审核中...)

前往app查看评论内容

#联合化疗#

君实生物特瑞普利单抗联合化疗一线治疗非小细胞肺癌的新适应症上市申请获受理

2021-12-12

科室
- - 订阅+
  - 更多科室
工具
服务